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In Europe and the United States, methicillin-
resistant  Staphylococcus aureus (MRSA) and
vancomycin-resistant enterococci (VRE) have
been widely disseminated in many medical
institutions; gram-negative rods, including Kleb-
siella pneumoniae and Escherichia coli produc-
ing extended-spectrum ß-lactamases (ESBLs),
are also becoming a clinical threat. In Japan,
many antimicrobial drugs, such as carbapenems,
fluoroquinolones, and aminoglycosides, have
been freely used as first-line drugs for more than
15 years. During that time, drug-resistant
bacteria have been emerging and proliferating (1-
3). Isolation of VRE and ESBL-producing gram-
negative rods is still rare (4), but MRSA and
penicillin-intermediate-resistant and penicillin-
resistant Streptococcus pneumoniae are widely
distributed in clinical settings (5), as in western
countries. In addition, several carbapenem- and
fluoroquinolone-resistant gram-negative rods




Many clinically effective antimicrobial drugs
have been developed by Japanese pharmaceuti-
cal companies since the 1960s. These drugs are
mainly broad-spectrum cephems, fluoroquinolo-
nes, macrolides, and aminoglycosides, which are
quite effective against various pathogenic
bacterial species. Moreover, the official prices of
these antimicrobial drugs are set at relatively
high levels compared with those of earlier drugs
such as penicillins, older quinolones, and
kanamycin. Therefore, newer drugs have been
used preferentially as first-line drugs under the
Japanese health insurance system, which allows
medical institutions to obtain benefit from the
difference between the official price (selling
price) and the actual market cost. In Japan, three
carbapenems (imipenem, panipenem, and mero-
penem) and at least nine fluoroquinolones
(enoxacin, fleroxacin, norfloxacin, ofloxacin,
ciprofloxacin, lomefloxacin, tosufloxacin, spar-
floxacin, and levofloxacin) are used as first-line
drugs in every clinical setting, although use of
these drugs is restricted in many western
countries, including the United States. Arbeka-
cin, clarithromycin, and teicoplanin are also
widely used for chemotherapy.
Drug-Resistant Bacteria
The following summary is based on a
preliminary survey of VRE and MRSA and a
report of surveillance for antimicrobial suscepti-
bility in Japan conducted by the Medical
Information System Development Center.
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Multidrug resistance in gram-positive bacteria has become common worldwide. In
Japan until recently, gram-negative bacteria such as Pseudomonas aeruginosa,
Klebsiella pneumoniae, and Serratia marcescens were controlled by carbapenems,
fluoroquinolones, and aminoglycosides. However, several of these microorganisms




Since vancomycin was approved for IV use in
1991 only for MRSA infections, isolation of VRE
is still rare in Japan; however, VanA-type
Enterococcus faecium was first isolated in Kyoto
in 1996 (9). Fewer than 50 cases of vanA- or vanB-
type VRE isolation have been reported through-
out Japan (unpublished data). An increase in
VRE isolation may be inevitable because of
international travel and importation of chicken
contaminated with VRE (10).
MRSA
The percentage of MRSA among nosocomial
S. aureus strains in Japan is estimated to be 50%
to 70%. Several deaths associated with MRSA
infection have been reported (11,12), despite
preventive measures against nosocomial infec-
tions. However, the actual number of deaths
associated with MRSA infection, as well as the
trend, is unknown.
Isolation of a vancomycin-homo-resistant
S. aureus strain Mu50 from a clinical sample in
Japan was reported in 1997 (13). This strain was
selected from  vancomycin-hetero-resistant  S. aureus
strain Mu3, which intrinsically contains a few
Mu50. Identifying Mu50 by the antibiotic
susceptibility testing method recommended by
the National Committee for Clinical Laboratory
Standards (NCCLS) (14) may be difficult.
Therefore, clinicians were concerned that
emergence of strains corresponding to Mu3 and
Mu50 could become a serious clinical problem.
We conducted a nationwide survey for MRSA
by collecting >6,600 clinical isolates from 245
medical settings. When >105 CFU of bacteria
were inoculated, 3% to 4% of clinical isolates grew
colonies on brain-heart-infusion agar (BHI agar)
plates containing 4 mg/L of vancomycin, as
recommended (13). However, the assay reproduc-
ibility was poor and we were unable to confirm a
stable resistant phenotype. Several vancomycin-
tolerant strains (MIC, 4 mg/L by NCCLS method)
were selected after repeated in vitro selection
with BHI agar plates containing sub-MIC
concentrations of vancomycin. No strain corre-
sponding to Mu50, which had an MIC for
vancomycin of 8 mg/L by the standard NCCLS
method, could be identified in 6,625 clinical
isolates. If strains with vancomycin-resistance
profiles similar to those of Mu3 or Mu50 were
widely disseminated in Japan,  vancomycin-
homo-resistant  strains such as Mu50 would be
expected in clinical settings and would be
isolated by the routine NCCLS antibiotic-
susceptibility testing method (15). Since vanco-
mycin has been in widespread use for nearly 9
years in Japan, several Mu50-like strains should
have been selected and predominant. Possibly
the Mu3 and Mu50 strains reported earlier are
unusual strains that may have critical defects or
mutations in the genes responsible for with
synthesis or degradation of the peptidoglycan
layer. The clinical importance and genetic
background of these strains need to be
elucidated. Clinicians should be alert for
emergence of glycopeptide-resistant Staphylo-
cocci that have acquired endogenous gene
mutations or exogenous genes responsible for
vancomycin resistance (e.g., the vanA or vanB
gene clusters found in VRE).
Glycopeptide-Resistant
Coagulase-Negative Staphylococci
Sporadic isolation of teicoplanin-resistant
coagulase-negative Staphylococci such as Sta-
phylococcus haemolyticus has been reported to
several medical, clinical, or microbiological
societies in Japan; however, no report has been
published in English.
Penicillin-Resistant Pneumococci
The overall isolation frequency of penicillin-
intermediate  S. pneumoniae and penicillin-
resistant  S. pneumoniae is estimated to be
approximately 50%, according to reports from
individual hospitals and health districts in Japan
(16,17). Several clinically isolated pneumococci
are resistant to cephems, new macrolides, and
fluoroquinolones (16,18). Nosocomial penicillin-
resistant S. pneumoniae isolates usually belong
to serotypes 19, 6, and 23 (19), and substitution at
Thr371 was associated with penicillin resistance




P. aeruginosa is resistant to a wide range of
antimicrobial drugs. Carbapenems, fluoroquino-
lones, and aminoglycosides such as amikacin are
the last resort for treatment. However, several
clinical isolates that have acquired resistance to574 Emerging Infectious Diseases Vol. 6, No. 6, November–December 2000
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these drugs have been identified in Japan. Of
special concern are highly carbapenem-resistant
strains producing plasmid-dependent IMP-1-
type metallo-ß-lactamase, which are proliferat-
ing rapidly (1). According to a preliminary survey
of 2,533 P. aeruginosa isolates, 88 (1.3%) strains
had the blaIMP gene cassette responsible for IMP-
1 production. Moreover, the blaIMP gene cassette
has been dispersing into various glucose-
nonfermenting gram-negative bacteria such as
Pseudomonas putida,  P. fluorescens, and
Burkholderia cepacia (7).
Furthermore, approximately 20% and 5% of
clinically isolated P. aeruginosa have acquired
resistance to fluoroquinolones and amikacin,
respectively. Alcaligenes and Acinetobacter spp.
have also acquired a wide range of drug resistance.
Enterobacteriaceae
Two nosocomial outbreaks of Serratia
marcescens were recently reported in Japan. This
bacterium is consistently resistant to penicillins
and classic cephalosporins (e.g., cephalothin and
cephaloridine), but not to carbapenems. Howev-
er, IMP-1 producers have recently been isolated
in geographically separate clinical settings, and
they often show high-level resistance to
ß-lactams, including cephamycins and carbapen-
ems (21). According to a preliminary survey of
3,222 clinically isolated S. marcescens strains, at
least 141 (4.4%) had IMP-1 productivity. Some of
these strains also have acquired resistance to
fluoroquinolones or amikacin.
E. coli and K. pneumoniae are still
susceptible to oxy-imino-cephalosporins such as
cefotaxime and ceftazidime. K. pneumoniae and
E. coli strains that produce TEM- or SHV-derived
extended-spectrum ß-lactamase and are resis-
tant to these drugs are still rare in Japan, while
those producing CTX-M-2 type ß-lactamase
predominate (22,23). This disproportion may be
related to the widespread use of cephamycins and
carbapenems. However, as a result of recent
restricted use of these broad-spectrum drugs,
several  K. pneumoniae and  E. coli strains
producing SHV-derived ESBLs, such as SHV-12,
are emerging (4,24).
Several multidrug-resistant Salmonella spp.
have been reported in Japan, and some of them
were recently identified as S. Typhimurium DT104
(25). However, isolation frequency of DT104 is
thought to be lower than in western countries.
Fluoroquinolone-resistant gonococci are also
increasing in Japan, as in south Asian countries
(26). Haemophilus influenzae clinical isolates that
show ampicillin resistance, some of which are
penicillinase nonproducers, have also been increas-
ing (27). More than 90% of Moraxella catarrhalis
have acquired penicillinase productivity.
Isolation frequency of multidrug-resistant
Mycobacterium tuberculosis is estimated to be
low (28) but may be increasing, as indicated by
recent reports of several outbreaks (29).
Drug-Resistant Bacteria
in the 21st Century
Multidrug-resistant gram-positive cocci such
as MRSA and VRE have emerged and spread
worldwide in the 20th century. Gram-negative
rods such as P. aeruginosa, K. pneumoniae, and
S. marcescens have until recently been controlled
by carbapenems, fluoroquinolones, and ami-
noglycosides. However, several of these microor-
ganisms have become resistant to many
antimicrobial drugs. Extraordinary efforts will
be needed to prevent global dissemination of
multidrug-resistant gram-negative bacteria in
the next millennium (30).
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